On November 9, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, will be featured in a Spotlight poster discussion session at the San Antonio Breast Cancer Symposium taking place December 4-8 in San Antonio (Press release, Syros Pharmaceuticals, NOV 9, 2018, View Source [SID1234531109]). The data show that SY-1365 has dose-dependent inhibitory activity in hormone receptor-positive breast cancer cell lines that are resistant to treatment with CDK4/6 inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract for this presentation is now available online on the SABCS website at View Source

Details on the presentation are as follows:

Presentation Title: Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor-positive breast cancer cells
Session Date & Time: Friday, December 7, 7:00-9:00 a.m. CT (8:00-10:00 a.m. ET)
Session Title: Spotlight Session 7: Lobular Breast Cancer
Presenter: Dr. Cristina Guarducci, Dana Farber Cancer Institute
Abstract Number: 1008
Program Number: PD7-12
Location: Stars at Night Ballroom, Henry B. Gonzalez Convention Center